<DOC>
	<DOCNO>NCT02566057</DOCNO>
	<brief_summary>This study evaluate whether prospective pharmacogenetic test cost-effective affect clinical treatment outcomes patient early-phase psychosis .</brief_summary>
	<brief_title>Prospective Pharmacogenetic Testing Clinical Outcomes Patients With Early-Phase Psychosis</brief_title>
	<detailed_description>Large scale clinical trial demonstrate substantial proportion patient psychotic disorder , schizophrenia bipolar disorder , discontinue antipsychotic medication due either lack efficacy intolerable side effect , extrapyramidal symptom ( EPS ) weight gain . In clinical practice , essentially trial error process decide best antipsychotic drug start switch failed trial little empirical data available guide clinician drug selection . One promising tool , potentially provide valuable information help guide medication management , pharmacogenetic test certain genetic variant associate psychiatric drug response . However , pharmacogenetic study date retrospective , prospective clinical trial evaluate clinical utility pharmacogenetic test guide clinical practice . Furthermore , unknown whether pharmacogenetic test cost effective . Until recently , pharmacogenetic test expensive time-consuming . New technology past year make possible cheap faster test . One company offer pharmacogenetic testing service , Genomind LLC , provide genotyping variant ( GeneceptTM Assay ) relevant psychiatric drug response . For example , serotonin 2C receptor gene ( HTR2C ) variant protect patient antipsychotic drug induce weight gain ( -759C/T , rs3813929 ) ; deletion variant dopamine D2 receptor gene ( DRD2 ) suggest poor efficacy antipsychotic drug treatment ( -141C Ins/Del , rs1799732 ) ; short allele serotonin transporter gene ( SLC6A4 ) associate antidepressant side effect . In present study , investigator propose conduct prospective , randomize , rater-blinded clinical trial test clinical utility cost-effectiveness pharmacogenetic test guide medication treatment patient recent-onset psychotic disorder . Patients assign either pharmacogenetic testing guide treatment condition ( PGT ) treatment usual condition ( TAU ) . In PGT condition , patient utilize GeneceptTM Assay result provide prescribers may use result guide medication management . In TAU condition , patient also utilize GeneceptTM Assay result provide back prescribers , treat patient without knowledge pharmacogenetic testing result . Pharmacogenetic testing may relevant recent-onset early stage illness past medication history typically use guide medication choice may available . Pharmacogenomic testing may particularly pertinent young patient tend medication na√Øve previous medication history guide future treatment . Pharmacogenomic testing may provide valuable information guide medication choice clinical practice .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>1 . Age 1564 ; 2 . Diagnostic Statistical Manual Diploma Social Medicine diagnosis schizophrenia ( DSM IV ) , schizoaffective disorder , schizophreniform disorder , psychotic disorder NOS , bipolar disorder ; 3 . Onset antipsychotic treatment within past 3 year ; 4 . Able provide inform consent . ( assent age 18 ) 1 . Evidence serious medical condition , 2 . Female patient pregnant breast feeding ; 3 . Patients willing take medication treatment ; 4 . Patients unable provide inform consent due impairment decisionmaking ability .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>